BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30347879)

  • 1. Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.
    Feurstein S; Thomay K; Hofmann W; Buesche G; Kreipe H; Thol F; Heuser M; Ganser A; Schlegelberger B; Göhring G
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
    Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
    Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
    Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic findings in primary and secondary MDS.
    Heim S
    Leuk Res; 1992; 16(1):43-6. PubMed ID: 1732669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
    Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
    Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
    Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
    Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
    Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
    Mallo M; Cervera J; Schanz J; Such E; García-Manero G; Luño E; Steidl C; Espinet B; Vallespí T; Germing U; Blum S; Ohyashiki K; Grau J; Pfeilstöcker M; Hernández JM; Noesslinger T; Giagounidis A; Aul C; Calasanz MJ; Martín ML; Valent P; Collado R; Haferlach C; Fonatsch C; Lübbert M; Stauder R; Hildebrandt B; Krieger O; Pedro C; Arenillas L; Sanz MÁ; Valencia A; Florensa L; Sanz GF; Haase D; Solé F
    Leukemia; 2011 Jan; 25(1):110-20. PubMed ID: 20882045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies.
    Anderson K; Arvidsson I; Jacobsson B; Hast R
    Cancer Genet Cytogenet; 2002 Jul; 136(2):101-7. PubMed ID: 12237232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
    Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
    Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPM1 deletion is associated with gross chromosomal rearrangements in leukemia.
    La Starza R; Matteucci C; Gorello P; Brandimarte L; Pierini V; Crescenzi B; Nofrini V; Rosati R; Gottardi E; Saglio G; Santucci A; Berchicci L; Arcioni F; Falini B; Martelli MF; Sambani C; Aventin A; Mecucci C
    PLoS One; 2010 Sep; 5(9):e12855. PubMed ID: 20877721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.
    Jerez A; Gondek LP; Jankowska AM; Makishima H; Przychodzen B; Tiu RV; O'Keefe CL; Mohamedali AM; Batista D; Sekeres MA; McDevitt MA; Mufti GJ; Maciejewski JP
    J Clin Oncol; 2012 Apr; 30(12):1343-9. PubMed ID: 22370328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOES THE PATTERN OF CLONAL EVOLUTION IN THE KARYOTYPE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES DEPEND ON THE TYPE OF THE PRIMARY CHROMOSOMAL ABERRATIONS?
    Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
    Tsitol Genet; 2015; 49(4):17-24. PubMed ID: 26419065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.